200 related articles for article (PubMed ID: 37328580)
1. Untargeted urinary metabolomics for bladder cancer biomarker screening with ultrahigh-resolution mass spectrometry.
Nizioł J; Ossoliński K; Płaza-Altamer A; Kołodziej A; Ossolińska A; Ossoliński T; Nieczaj A; Ruman T
Sci Rep; 2023 Jun; 13(1):9802. PubMed ID: 37328580
[TBL] [Abstract][Full Text] [Related]
2. Untargeted ultra-high-resolution mass spectrometry metabolomic profiling of blood serum in bladder cancer.
Nizioł J; Ossoliński K; Płaza-Altamer A; Kołodziej A; Ossolińska A; Ossoliński T; Ruman T
Sci Rep; 2022 Sep; 12(1):15156. PubMed ID: 36071106
[TBL] [Abstract][Full Text] [Related]
3. Untargeted metabolomics of bladder tissue using liquid chromatography and quadrupole time-of-flight mass spectrometry for cancer biomarker detection.
Nizioł J; Ossoliński K; Płaza-Altamer A; Kołodziej A; Ossolińska A; Ossoliński T; Krupa Z; Ruman T
J Pharm Biomed Anal; 2024 Mar; 240():115966. PubMed ID: 38217999
[TBL] [Abstract][Full Text] [Related]
4. Targeted and untargeted urinary metabolic profiling of bladder cancer.
Ossoliński K; Ruman T; Copié V; Tripet BP; Kołodziej A; Płaza-Altamer A; Ossolińska A; Ossoliński T; Nieczaj A; Nizioł J
J Pharm Biomed Anal; 2023 Sep; 233():115473. PubMed ID: 37229797
[TBL] [Abstract][Full Text] [Related]
5. LC-MS metabolomics of urine reveals distinct profiles for non-muscle-invasive and muscle-invasive bladder cancer.
Oto J; Fernández-Pardo Á; Roca M; Plana E; Cana F; Herranz R; Pérez-Ardavín J; Vera-Donoso CD; Martínez-Sarmiento M; Medina P
World J Urol; 2022 Oct; 40(10):2387-2398. PubMed ID: 36057894
[TBL] [Abstract][Full Text] [Related]
6. Bladder cancer biomarker discovery using global metabolomic profiling of urine.
Wittmann BM; Stirdivant SM; Mitchell MW; Wulff JE; McDunn JE; Li Z; Dennis-Barrie A; Neri BP; Milburn MV; Lotan Y; Wolfert RL
PLoS One; 2014; 9(12):e115870. PubMed ID: 25541698
[TBL] [Abstract][Full Text] [Related]
7. Urinary metabolomics for discovering metabolic biomarkers of bladder cancer by UPLC-MS.
Wang R; Kang H; Zhang X; Nie Q; Wang H; Wang C; Zhou S
BMC Cancer; 2022 Feb; 22(1):214. PubMed ID: 35220945
[TBL] [Abstract][Full Text] [Related]
8. Bladder cancer biomarker screening based on non-targeted urine metabolomics.
Li J; Cheng B; Xie H; Zhan C; Li S; Bai P
Int Urol Nephrol; 2022 Jan; 54(1):23-29. PubMed ID: 34850327
[TBL] [Abstract][Full Text] [Related]
9. Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method.
Zhou Y; Song R; Ma C; Zhou L; Liu X; Yin P; Zhang Z; Sun Y; Xu C; Lu X; Xu G
Oncotarget; 2017 Mar; 8(13):20719-20728. PubMed ID: 28157703
[TBL] [Abstract][Full Text] [Related]
10. Three serum metabolite signatures for diagnosing low-grade and high-grade bladder cancer.
Tan G; Wang H; Yuan J; Qin W; Dong X; Wu H; Meng P
Sci Rep; 2017 Apr; 7():46176. PubMed ID: 28382976
[TBL] [Abstract][Full Text] [Related]
11. Metabolic Evaluation of Urine from Patients Diagnosed with High Grade (HG) Bladder Cancer by SPME-LC-MS Method.
Łuczykowski K; Warmuzińska N; Operacz S; Stryjak I; Bogusiewicz J; Jacyna J; Wawrzyniak R; Struck-Lewicka W; Markuszewski MJ; Bojko B
Molecules; 2021 Apr; 26(8):. PubMed ID: 33920347
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis of bladder cancer and prediction of survival by urinary metabolomics.
Jin X; Yun SJ; Jeong P; Kim IY; Kim WJ; Park S
Oncotarget; 2014 Mar; 5(6):1635-45. PubMed ID: 24721970
[TBL] [Abstract][Full Text] [Related]
13. Searching for urine biomarkers of bladder cancer recurrence using a liquid chromatography-mass spectrometry and capillary electrophoresis-mass spectrometry metabolomics approach.
Alberice JV; Amaral AF; Armitage EG; Lorente JA; Algaba F; Carrilho E; Márquez M; García A; Malats N; Barbas C
J Chromatogr A; 2013 Nov; 1318():163-70. PubMed ID: 24139504
[TBL] [Abstract][Full Text] [Related]
14. Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery.
Liu X; Cheng X; Liu X; He L; Zhang W; Wang Y; Sun W; Ji Z
Int J Cancer; 2018 Jul; 143(2):408-418. PubMed ID: 29451296
[TBL] [Abstract][Full Text] [Related]
15. Metabolomics of Non-muscle Invasive Bladder Cancer: Biomarkers for Early Detection of Bladder Cancer.
Cheng X; Liu X; Liu X; Guo Z; Sun H; Zhang M; Ji Z; Sun W
Front Oncol; 2018; 8():494. PubMed ID: 30450336
[No Abstract] [Full Text] [Related]
16. Volatile metabolomic signature of bladder cancer cell lines based on gas chromatography-mass spectrometry.
Rodrigues D; Pinto J; Araújo AM; Monteiro-Reis S; Jerónimo C; Henrique R; de Lourdes Bastos M; de Pinho PG; Carvalho M
Metabolomics; 2018 Apr; 14(5):62. PubMed ID: 30830384
[TBL] [Abstract][Full Text] [Related]
17. LC-MS/MS platform-based serum untargeted screening reveals the diagnostic biomarker panel and molecular mechanism of breast cancer.
Gong S; Wang Q; Huang J; Huang R; Chen S; Cheng X; Liu L; Dai X; Zhong Y; Fan C; Liao Z
Methods; 2024 Feb; 222():100-111. PubMed ID: 38228196
[TBL] [Abstract][Full Text] [Related]
18. A urinary microRNA (miR) signature for diagnosis of bladder cancer.
Hofbauer SL; de Martino M; Lucca I; Haitel A; Susani M; Shariat SF; Klatte T
Urol Oncol; 2018 Dec; 36(12):531.e1-531.e8. PubMed ID: 30322728
[TBL] [Abstract][Full Text] [Related]
19. Urinary proteomics and metabolomics studies to monitor bladder health and urological diseases.
Chen Z; Kim J
BMC Urol; 2016 Mar; 16():11. PubMed ID: 27000794
[TBL] [Abstract][Full Text] [Related]
20. Profilin 1 is a potential biomarker for bladder cancer aggressiveness.
Zoidakis J; Makridakis M; Zerefos PG; Bitsika V; Esteban S; Frantzi M; Stravodimos K; Anagnou NP; Roubelakis MG; Sanchez-Carbayo M; Vlahou A
Mol Cell Proteomics; 2012 Apr; 11(4):M111.009449. PubMed ID: 22159600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]